Abiologics is pioneering the development of Synteins™, a transformational class of macromolecular medicines unlocked by novel synthetic and computational technologies
Job Summary
Abiologics is pioneering the development of Synteins™, a transformational class of macromolecular medicines unlocked by novel synthetic and computational technologies.
The successful candidate will lead projects in designing, synthesizing, and optimizing novel miniprotein therapeutics called Synteins™.
Contribute to patent applications and scientific publications, showcasing lab innovation.
Matching Summary
Abiologics is pioneering the development of Synteins™, a transformational class of macromolecular medicines unlocked by novel synthetic and computational technologies.